Chengdu, China

Shuangyan Tan

This inventor holds 1 USPTO granted patent. Top assignee: Sichuan University. Active years: 2023.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Shuangyan Tan in Tumor Biomarker Detection.

Introduction

Shuangyan Tan is an accomplished inventor based in Chengdu, China. She has made significant contributions to the field of cancer research, particularly in the detection of tumor biomarkers. Her innovative work focuses on improving diagnostic methods for non-small cell lung cancer.

Latest Patents

Shuangyan Tan holds a patent for "Methods of detecting an EML4-ALK fusion tumor biomarker." This patent discloses a tumor biomarker and its application, along with a tumor detection kit. The invention identifies a specific circular RNA present in the blood of patients suffering from non-small cell lung cancer, which contains an EML4-ALK or SLC34A2-ROS1 fusion gene. The circular RNA is associated with the disease and is known to exist stably in plasma samples, demonstrating high specificity and effectiveness as a biomarker for tumor detection. The patent also includes reagents such as primers and probes for preparing the tumor detection kit.

Career Highlights

Shuangyan Tan is affiliated with Sichuan University, where she continues her research and development in the field of oncology. Her work has the potential to significantly impact the early detection and treatment of lung cancer, providing hope for improved patient outcomes.

Collaborations

Shuangyan Tan collaborates with notable colleagues, including Yong Peng and Yuquan Wei, who contribute to her research efforts and advancements in tumor biomarker detection.

Conclusion

Shuangyan Tan's innovative work in tumor biomarker detection exemplifies the importance of research in improving cancer diagnostics. Her contributions are paving the way for more effective detection methods, ultimately benefiting patients with non-small cell lung cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…